Universal cell therapy for tough-to-treat inflammatory bowel disease
Part of Digestive system clinical trials.
This trial tests a new universal cell therapy called CNK-UT009 for people with moderate-to-severe inflammatory bowel disease (IBD) that hasn't responded to other treatments. It aims to see if the therapy is safe and effective for patients who have limited options left.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate-to-severe Crohn's disease or ulcerative colitis (inflammatory bowel disease)
- You have tried at least two biologic drugs or small molecule drugs and they didn't work, or you have had two or more intestinal surgeries with ongoing symptoms
- Your bone marrow and major organs (like liver and kidneys) are working well
- You are not pregnant and agree not to become pregnant during the study
- You are willing to follow the study rules and attend all visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This trial tests a new drug called BCD-261 for people with moderate to severe ulcerative colitis that hasn't gotten better with standard treatments. It aims to see if the drug can improve symptoms and how safe it is.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to treat inflammatory bowel disease (IBD) that has not responded to standard treatments. The therapy is engineered to target specific immune cells involved in IBD inflammation.
This trial tests a new type of immune cell therapy called CAR-T cells, which target two proteins (CD19 and BCMA) to reduce inflammation in the gut. It is designed for adults with moderate to severe ulcerative colitis or Crohn's disease that has not responded well to other treatments.
This trial tests a new treatment using your own immune cells (called CAR-T cells) to calm down the immune attack that causes ulcerative colitis. It is for people with moderate to severe colitis who have not gotten better with standard medicines.
This trial tests a new treatment called CMTS0929 for people with inflammatory bowel disease (IBD), a condition that causes inflammation in the digestive tract. It aims to see if the treatment works and is safe.
Hear when a new Inflamatory Bowel Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.